APA

Kumar S., Flinn I., Richardson P. G., Hari P., Callander N., Noga S. J., Stewart A. K., Turturro F., Rifkin R., Wolf J., Estevam J., Mulligan G., Shi H., Webb I. J. & Rajkumar S. V. (20120716). Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. : Blood.

Chicago

Kumar Shaji, Flinn Ian, Richardson Paul G, Hari Parameswaran, Callander Natalie, Noga Stephen J, Stewart A Keith, Turturro Francesco, Rifkin Robert, Wolf Jeffrey, Estevam Jose, Mulligan George, Shi Hongliang, Webb Iain J and Rajkumar S Vincent. 20120716. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. : Blood.

Harvard

Kumar S., Flinn I., Richardson P. G., Hari P., Callander N., Noga S. J., Stewart A. K., Turturro F., Rifkin R., Wolf J., Estevam J., Mulligan G., Shi H., Webb I. J. and Rajkumar S. V. (20120716). Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. : Blood.

MLA

Kumar Shaji, Flinn Ian, Richardson Paul G, Hari Parameswaran, Callander Natalie, Noga Stephen J, Stewart A Keith, Turturro Francesco, Rifkin Robert, Wolf Jeffrey, Estevam Jose, Mulligan George, Shi Hongliang, Webb Iain J and Rajkumar S Vincent. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. : Blood. 20120716.